Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, BIOGEN INC. reported revenue of $9.89B, up 2.2% year over year. Operating margin was 15.7% and net margin 13.1%, on a free-cash-flow margin of 20.7% with capital expenditure at 1.6% of revenue. Every figure is computed directly from BIIB's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $9.89B | 15.7% | 13.1% |
| FY2024 | $9.68B | 19.7% | 16.9% |
| FY2023 | $9.84B | 13.2% | 11.8% |
| FY2022 | $10.17B | 35.3% | 29.9% |
| FY2021 | $10.98B | 25.9% | 14.2% |
How does BIIB compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.